In this article, we will discuss Olaparib (Renal Impairment). So, let’s get started.
No adjustment to the starting dose is required in patients with mild renal impairment, but patients should be monitored closely for toxicity. A 24% increase in mean exposure (AUC) was observed in patients with mild renal impairment (CLcr = 51-80 mL/min) compared to patients with normal renal function (CLcr >80 mL/min). A 44% increase in AUC was observed in patients with moderate renal impairment (CLcr = 31-50 mL/min) compared to patients with normal renal function (CLcr >80 mL/min). For patients with moderate renal impairment, reduce the dose of Olaparib to 200 mg twice daily. There are no data in patients with severe renal impairment or end-stage disease (CLcr ≤30 mL/min).